CD274 and non-small cell lung carcinoma: In the present meta-analysis, we compared the efficacy and safety of Niv+Ipi and existing regimens with immunotherapies with a PBC as a common comparator in patients with PD-L1-positive advanced NSCLC using the statistical method of a Bayesian NMA.